These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 308663)

  • 1. Catecholamine levels in the whole brain and the probability of memory formation are not related.
    Palfai T; Brown OM; Walsh TJ
    Pharmacol Biochem Behav; 1978 Jun; 8(6):717-21. PubMed ID: 308663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation between seizure susceptibility and brain catecholamine levels. An experimental study using a kindling preparation].
    Sato M; Nakashima T; Mitsunobu K; Otsuki S
    No To Shinkei; 1976 May; 28(5):471-7. PubMed ID: 140696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral catecholamines and memory: characteristics of syrosingopine-induced amnesia.
    Walsh TJ; Palfai T
    Pharmacol Biochem Behav; 1979 Oct; 11(4):449-52. PubMed ID: 42929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of biogenic amines in memory formation.
    Dismukes RK; Rake AV
    Psychopharmacologia; 1972; 23(1):17-25. PubMed ID: 4259732
    [No Abstract]   [Full Text] [Related]  

  • 5. Behavior and biochemical effects of preferentially protecting monoamines in the brain against the action of reserpine.
    Butcher LL; Rhodes DL; Yuwiler A
    Eur J Pharmacol; 1972 May; 18(2):204-12. PubMed ID: 4537669
    [No Abstract]   [Full Text] [Related]  

  • 6. 5-Hydroxytryptophan reversal of reserpine enhancement of audiogenic seizure susceptibility in mice.
    Boggan WO; Seiden LS
    Physiol Behav; 1973 Jan; 10(1):9-12. PubMed ID: 4540511
    [No Abstract]   [Full Text] [Related]  

  • 7. Behavioral and catecholamine depleting effects of alpha-methyl-5-hydroxytryptophan.
    Dominic JA; Moore KE
    Eur J Pharmacol; 1969 Dec; 8(3):292-5. PubMed ID: 5308817
    [No Abstract]   [Full Text] [Related]  

  • 8. [The brain catecholamine systems in the regulation of dominance].
    Serova LI; Naumenko EV
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1990; 40(3):490-6. PubMed ID: 1975967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain catecholamines modifications. The effects on memory facilitation induced by oxotremorine in mice.
    Huygens P; Baratti CM; Gardella JL; Filinger E
    Psychopharmacology (Berl); 1980; 69(3):291-4. PubMed ID: 6774370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse brain catecholamines, 5-hydroxytryptamine and the antinociceptive activity of pethidine.
    Pleuvry BJ
    Eur J Pharmacol; 1975 Dec; 34(2):351-61. PubMed ID: 1234554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of L-dopa reversal of reserpine-induced conditioned avoidance response suppression by disulfiram.
    Seiden LS; Peterson DD
    J Pharmacol Exp Ther; 1968 Sep; 163(1):84-90. PubMed ID: 5673718
    [No Abstract]   [Full Text] [Related]  

  • 12. Aging-related changes in retrograde amnesia for mice.
    Essman WB
    Gerontology; 1982; 28(5):303-13. PubMed ID: 6890009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of catecholamine precursors and monoamine oxidase inhibition on the amine levels of central catecholamine neurons after reserpine treatment or tyrosine hydroxylase inhibition.
    Corrodi H; Fuxe K
    Life Sci; 1967 Jul; 6(13):1345-50. PubMed ID: 6035763
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of catecholamines on the central nervous system. (1). Role of dopamine in the brain in animal behavioral changes].
    Kameyama T; Kisara K
    Nihon Yakurigaku Zasshi; 1966 Sep; 62(5):317-26. PubMed ID: 5298294
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of L-DOPA on brain catecholamines and motility in rats.
    Maj J; Grabowska M; Mogilnicka E
    Psychopharmacologia; 1971; 22(2):162-71. PubMed ID: 5124189
    [No Abstract]   [Full Text] [Related]  

  • 16. Behavioral effects of alpha-methyltyrosine after prior depletion of brain catecholamines.
    Rech RH; Carr LA; Moore KE
    J Pharmacol Exp Ther; 1968 Apr; 160(2):326-35. PubMed ID: 5651375
    [No Abstract]   [Full Text] [Related]  

  • 17. L-dopa hypotension in dogs: evidence for mediation through 5-HT release.
    Antonaccio MJ; Robson RD
    Arch Int Pharmacodyn Ther; 1974 Nov; 212(1):89-102. PubMed ID: 4281293
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the effects of losulazine and reserpine on central aminergic neurons.
    Pan JT; Hooth MJ; Lookingland KJ; Moore KE; Marks TA
    Toxicol Appl Pharmacol; 1993 Nov; 123(1):26-33. PubMed ID: 8236258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficits of escape performance following catecholamine depletion: implications for behavioral deficits induced by uncontrollable stress.
    Anisman H; Irwin J; Sklar LS
    Psychopharmacology (Berl); 1979 Aug; 64(2):163-70. PubMed ID: 115036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological correlates of ECS induced disruption of a passive avoidance task in mice.
    Boggan WO; Schlesinger K
    Behav Biol; 1974 Sep; 12(1):127-34. PubMed ID: 4547965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.